Inhibitory effect of atorvastatin on the cell growth of cardiac myxomas via the PTEN and PHLPP2 phosphatase signaling pathway

Oncology Reports

Volumn 30, Issue 2, 2013, Pages 757-762

  Wu, Xing Li ^a   Yang, Ding You ^a   Tan, Duan Jun ^b   Yao, Heng Chen ^c   Chai, Wenhui ^d   Peng, Li ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c Liaocheng City Hospital   (China)

^d Changji City Hospital   (China)

Author keywords

Atorvastatin; Cardiac myxoma cells; IGF 1; PHLPP; PTEN

Indexed keywords

ATORVASTATIN; PHLPP1 PROTEIN; PHLPP2 PROTEIN; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HEART MYXOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR CELL;

CELL PROLIFERATION; HEART NEOPLASMS; HEPTANOIC ACIDS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; MYXOMA; PHOSPHOPROTEIN PHOSPHATASES; PTEN PHOSPHOHYDROLASE; PYRROLES; SIGNAL TRANSDUCTION;

EID: 84879647941     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2501     Document Type: Article

References (44)

1. Roschkov S, Rebeyka D, Mah J and Urquhart G: The dangers of cardiac myxomas. Prog Cardiovasc Nurs 22: 27-30, 2007.
2. Wilkes D, McDermott DA and Basson CT: Clinical phenotypes and molecular genetic mechanisms of Carney complex. Lancet Oncol 6: 501-508, 2005. (Pubitemid 40903631)
3. Figueroa-Torres Y, Martínez-Ojeda JA, Franqui-Rivera H, et al: Benign cardiac neoplasms: the experience at the Cardiovascular Center of Puerto Rico and the Caribbean. PR Health Sci J 27: 373-376, 2008.
4. Wu X, Yang D, Yang Z, et al: Clinical characteristics and long term post-operative outcome of cardiac myxoma. EXCLI J 11: 240-249, 2012.
5. Barh D, Kumar A, Chatterjee S and Liloglou T: Molecular features, markers, drug targets, and prospective targeted therapeutics in cardiac myxoma. Curr Cancer Drug Targets 9: 705-716, 2009.
6. Chu PH, Jung SM, Yeh TS, et al: MUC1, MUC2 and MUC5AC expressions in cardiac myxoma. Virchows Arch 446: 52-55, 2005.
7. Orlandi A, Ciucci A, Ferlosio A, et al: Increased expression and activity of matrix metalloproteinases characterize embolic cardiac myxomas. Am J Pathol 166: 1619-1628, 2005. (Pubitemid 40734385)
8. Sakamoto H, Sakamaki T, Kanda T, et al: Vascular endothelial growth factor is an autocrine growth factor for cardiac myxoma cells. Circ J 68: 488-493, 2004. (Pubitemid 38657539)
9. Fujisawa H, Koide N, Kono T, et al: Expression of basic fibroblast growth factor and its receptor-1 in cardiac myxoma. J Cardiovasc Surg 43: 589-594, 2002. (Pubitemid 35414686)
10. Amano J, Kono T, Wada Y, et al: Cardiac myxoma: its origin and tumor characteristics. Ann Thorac Cardiovasc Surg 9: 215-221, 2003.
11. Uzoh CC, Holly JMP, Biernacka KM, et al: Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel. Br J Cancer 104: 1587-1593, 2011.
12. Rzucidlo EM: Signaling pathways regulating vascular smooth muscle cell differentiation. Vascular 17 (Suppl 1): S15-S20, 2009.
13. Perks C: The role of insulin-like growth factor binding proteins. Neuroendocrinology 83: 154-160, 2006.
14. Mateus C, Palangié A, Franck N, et al: Heterogeneity of skin manifestations in patients with Carney complex. J Am Acad Dermatol 59: 801-810, 2008.
15. Raff SB, Carney JA, Krugman D, et al: Prolactin secretion abnormalities in patients with the 'syndrome of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas' (Carney complex). J Pediatr Endocrinol Metab 13: 373-379, 2000. (Pubitemid 30202253)
16. Kurtkaya-Yapicier O, Scheithauer BW, Carney JA, et al: Pituitary adenoma in Carney complex: an immunohistochemical, ultrastructural, and immunoelectron microscopic study. Ultrastruct Pathol 26: 345-353, 2002. (Pubitemid 36016042)
17. Wahdan-Alaswad RS, Song K, Krebs T, et al: Insulin-like growth factor I suppresses bone morphogenetic protein signaling in prostate cancer cells by activating mTOR signaling. Cancer Res 70: 9106-9117, 2012.
18. Grimberg A: Mechanisms by which IGF-I may promote cancer. Cancer Biol Ther 2: 630-635, 2003.
19. Liu B, Lee KW, Anzo M, et al: Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. Oncogene 26: 1811-1819, 2007. (Pubitemid 46426204)
20. Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002. (Pubitemid 37328931)
21. Waalkes S, Simon P, Hennenlotter J, et al: Altered expression of Akt signaling pathway parameters in prostate needle biopsies derived from benign, adjacent and cancerous tissue. Oncol Rep 23: 1257-1260, 2010.
22. Falbo V, Floridia G, Censi F, et al: Three cases of rare salivary gland tumours: a molecular study of TP53, CDKN2A/ARF, RAS, BRAF, PTEN, MAPK2 and EGFR genes. Oncol Rep 26: 3-11, 2011.
23. Tserga A, Michalopoulos NV, Levidou G, et al: Association of aberrant DNA methylation with clinicopathological features in breast cancer. Oncol Rep 27: 1630-1638, 2012.
24. Bouali S, Chrétien AS, Ramacci C, et al: PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wildtype, hormone refractory prostate cancer cells. Oncol Rep 21: 731-735, 2009.
25. Jang K, Kim M, Seo HS, et al: PTEN sensitizes MDA-MB-468 cells to inhibition of MEK/Erk signaling for the blockade of cell proliferation. Oncol Rep 24: 787-793, 2010.
26. Garcia JA and Danielpour D: Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 7: 1347-1354, 2008.
27. Wu XL, Yang DY, Yang ZS, et al: Effect of IGF-1 on PI3K/PTEN signal pathway in vascular smooth muscle cell. Zhongguo Ying Yong Sheng Li Xue Za Zhi 20: 259-262, 2004 (In Chinese).
28. Brognard J, Sierecki E, Gao T, et al: PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell 25: 917-931, 2007. (Pubitemid 46436532)
29. Gao T, Brognard J and Newton AC: The phosphatase PHLPP controls the cellular levels of protein kinase C. J Biol Chem 283: 6300-6311, 2008.
30. McCarty MF: Suppression of dolichol synthesis with isoprenoids and statins may potentiate the cancer-retardant efficacy of IGF-I down-regulation. Med Hypotheses 56: 12-16, 2001.
31. Martínez-González J, Viñals M, Vidal F, et al: Mevalonate deprivation impairs IGF-I/insulin signaling in human vascular smooth muscle cells. Atherosclerosis 135: 213-223, 1997. (Pubitemid 28015188)
32. Miraglia E, Högberg J and Stenius U: Statins exhibit anticancer effects through modifications of the pAkt signaling pathway. Int J Oncol 40: 867-875, 2012.
33. Duncan RE, El-Sohemy A and Archer MC: Statins and cancer development. Cancer Epidemiol Biomarkers Prev 14: 1897-1898, 2005. (Pubitemid 41161197)
34. Bonovas S, Filioussi K, Tsavaris N, et al: Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol 24: 4808-4817, 2006. (Pubitemid 46655612)
35. Chan KK, Oza AM and Siu LL: The statins as anticancer agents. Clin Cancer Res 9: 10-19, 2003. (Pubitemid 36109711)
36. Lutski M, Shalev V, Porath A and Chodick G: Continuation with statin therapy and the risk of primary cancer: a population-based study. Prev Chronic Dis 9: E137, 2012.
37. Brown M, Hart C, Tawadros T, et al: The differential effects of statins on the metastatic behaviour of prostate cancer. Br J Cancer 106: 1689-1696, 2012.
38. Parada B, Reis F, Pinto A, et al: Chemopreventive efficacy of atorvastatin against nitrosamine-induced rat bladder cancer: antioxidant, anti-proliferative and anti-inflammatory properties. Int J Mol Sci 13: 8482-8499, 2012.
39. Lai SW, Liao KF, Lai HC, et al: Atorvastatin correlates with decreased risk of esophageal cancer: a population-based casecontrol study from Taiwan. Libyan J Med 7: 18830, 2012.
40. Miyamoto S, Purcell NH, Smith JM, et al: PHLPP-1 negatively regulates Akt activity and survival in the heart. Circ Res 107: 476-484, 2010.
41. Nitsche C, Edderkaoui M, Moore RM, et al: The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation. Gastroenterology 142: 377-387, 2012.
42. Mulholland DJ, Tran LM, Li Y, et al: Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19: 792-804, 2011.
43. Lee JK, Edderkaoui M, Truong P, et al: NADPH oxidase promotes pancreatic cancer cell survival via inhibiting JAK2 dephosphorylation by tyrosine phosphatases. Gastroenterology 133: 1637-1648, 2007. (Pubitemid 350029743)
44. Mistafa O, Ghalali A, Kadekar S, et al: Purinergic receptor-mediated rapid depletion of nuclear phosphorylated Akt depends on pleckstrin homology domain leucine-rich repeat phosphatase, calcineurin, protein phosphatase 2A, and PTEN phosphatases. J Biol Chem 285: 27900-27910, 2010.